Induction of drug resistance in embryonal rhabdomyosarcoma treated with conventional chemotherapy is associated with HLA class I increase

Neoplasma

Volumn 53, Issue 3, 2006, Pages 226-231

  Prados, J ^a   Melguizo, C ^a,b   Fernandez J E ^a   Carrillo, E ^a   Marchal, J A ^a,c   Boulaiz, H ^a,c   Martinez A ^a,c   Rodriguez Serrano, F ^a,c   Aranega A ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF ALMERÍA   (Spain)

^c UNIVERSITY OF JAÉN   (Spain)

Author keywords

HLA class 1; mdr1; Multidrug resistance; P glycoprotein; Rhabdomyosarcoma

Indexed keywords

DACTINOMYCIN; GLYCOPROTEIN P; HLA ANTIGEN CLASS 1; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL GROWTH; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYONAL RHABDOMYOSARCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; PLASMA CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

EID: 33744908613     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. RANEY RB. Soft-tissue sarcoma in childhood and adolescence. Curr Oncol Rep 2002; 4: 291-298.
2. FERRARI A, CASANOVA M. Current chemotherapeutic strategies for rhabdomyosarcoma. Expert Rev Anticancer Ther 2005; 5: 283-294.
3. ATRA A, PINKERTON R. High-dose chemotherapy in soft tissue sarcoma in children. Crit Rev Oncol Hematol 2002; 41: 191-196.
4. ICRISHNA R, MAYER LD. Multidrug resistance (MDR) in cancer. Mechanism, reversal using modulators and the role of MDR modulators in influencing the pharmacokinetics of anticancer. Eur J Pharm Sci 2000; 11: 265-283.
5. KOMDEUR R, PLAAT BE, VAN DER GRAF WT, HOEKSTRA HJ, HOLLEMA H et al. Expression of multidrug resistance proteins, P-gp, MRP1 and LRP, in soft tissue sarcomas analysed according to their histological type and grade. Eur J Cancer 2003; 39: 909-916.
6. AMBUDKAR SV, KIMCHI-SARFATY C, SAUNA ZE, GOTTESMAN MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468-7685.
7. BREIER A, BARANCIK M, SULOVA Z, UHRIK B. P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 2005; 5: 457-468.
8. LEUSCHNER I, HEUER T, HARMS D. Induction of drug resistance in human rhabdomyosarcoma cell lines is associated with increased maturation: possible explanation for differentiation in recurrences. Pediatr Devel Pathol 2002; 5: 276-282.
9. MELGUIZO C, PRADOS J, ANEIROS J, FERNANDEZ JE, VELEZ C et al. Differentiation of a human rhabdomyosarcoma cell line after antineoplastic drug treatment. J Pathol 1995; 175: 23-39.
10. MELGUIZO C, PRADOS J, MARCHALJA, VELEZ C, CARRILO E et al. Expression of HLA Class I but not HLA Class II antigens is modulated by P-glycoprotein in resistant human rhabdomyosarcoma cells. Neoplasma 2003; 50: 91-96.
11. GARCIA-LORA A, ALGARRA I, GARRIDO F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003; 195: 346-355.
12. RAMNATH N, TAN D, LI Q, HYLANDER BL, BOGNER P et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother 2005; 27: 1-9.
13. OLDFORD SA, ROBB JD, WATSON PH, DROVER S. HLA-DRB alleles are differentially expressed by tumor cells in breast carcinoma. Int J Cancer 2004; 112: 399-406.
14. NEWTON WA JR, GEHAN EA, WEBBER BL, MARSDEN HB, VAN UNNIK AJ et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification - an Intergroup Rhabdomyosarcoma Study. Cancer 1995; 76: 1073-1085.
15. CAO L, DUCHROW M, WINDHÖVEL U, KUJATH P, BRUCH HP et al. Expression of MDR1 mRNA and encoding P-glycoprotein in archival formalin-fixed paraffin-embedded gall bladder cancer tissues. Eur J Cancer 1998; 34: 1612-1617.
16. FERNÁNDEZ JE, CONCHA A, ARÁNEGA A, RUIZ-CABELLO F, CABRERA T et al. HLA I and II expression in rhabdomyosarcomas. Immunobiology 1991; 182: 440-448.
17. KOMDEUR R, KLUNDER J, VAN DER GRAFF WT, VAN DEN BERG E, DE BONT ES et al. Multidrug resistance proteins in rhabdomyosarcoma: comparison between children and adults. Cancer 2003; 97: 1999-2005.
18. ERALP Y, BAVBEK S, BASARAN M, KAYTAN E, YAMAN F, BILGIC B et al. Prognostic factors and survival in late adolescent and adult patients with small round cell tumors. Am J Clin Oncol 2002; 25: 418-424.
19. GALLEGO S, LLORT A, PARAREDA A, SANCHEZ DE TOLEDO J. Expression of multidrug resistance-1 and multidrug resistance-associated protein genes in pediatric rhabdomyosarcoma. Oncol Rep 2004; 11: 179-183.
20. STAIBANO S, FRANCO R, MEZZA E, LO MUZIO L, STRIANESE D et al. Orbital rhabdomyosarcoma: relationship between DNA ploidy, p53, bcl-2, MDR-1 and Ki67 (MIB1) expression and clinical behavior. Anticancer Res 2004, 24: 249-257.
21. RITZ U, DREXLER I, SUTTER D, ABELE R, HUBER C et al. Impaired transporter associated with antigen processing (TAP) function attributable to a single amino acid alteration in the peptide TAP subunit TAP1. J Immunol 2003; 170: 941-946.
22. ZOCHBAUER S, SCHWARZINGER I, STROBL H, LECHNER K, PIRKER R. Relationship between MDR1 gene and surface markers in acute myeloid leukemia. Anticancer Res 1997; 17: 749-752.
23. HIROSE M, HAMANO S, TOBINAIK K, KUROA Y. Cytosidal activity of PBL, LAK and IDEC-C2B8 and expression of HLA class 1, ICAM-1, and CD20 in vincristine-resistant hematologic cell lines. J Hemother 1999; 22: 237-244.
24. MARTIN-OROZCO E, FERRAGUT JA, GARCIA-PENARRUBIA P, FERRER-MONTIEL. Acquisition of multidrug resistance by L1210 leukemia cells decreases their tumorigenicity and enhances their susceptibility to the host immune response. Cancer Immunol Immunother 2005; 54: 328-336.
25. MASCI AM, SCALA S, RACIOPPI L, ZAPPACOSTA S. Cell surface expression of major histocompatibility class I antigens is modulated by P-glycoprotein transporter. Human Immunol 1995; 42: 245-253.
26. LEUSCHNER I, HARMS D, MATTKE A, KOSCIELNIAK E, TREUNER J. Rhabdomyosarcoma of the urinary bladder and vagina: a clinicophatologic study with emphasis of recurrent disease: a report of the Kiel Pediatric Tumor Registry and the German CWS Study. Am J Surg Pathol 2001; 25: 856-864.
27. GARCIA-LORA A, ALGARRA I, COLLADO A, GARRIDO F. Tumour immunology, vaccination and escape strategies. Eur J Immunogenet 2003; 30: 177-183.
28. SELIGER B, CABRERA T, GARRIDO F, FERRONE S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002; 12: 3-13.